NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of…
“Combining [brequinar] with either of two FDA-authorized COVID-19 treatments—Gilead’s remdesivir or Merck’s molnupiravir—makes these drugs more potent, according to a study done by researchers at the University of Maryland and University of Pennsylvania…The combo drugs stunted the growth of…
Nature explores why a comprehensive strategy for pandemic preparedness includes a library of therapeutic options and a model for productive collaborations. The reporter, Max Kozlov, writes: Researchers should also develop…
Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery This CRADA was initiated as part of the Antiviral Program for Pandemics (APP) Via…
Clear Creek Bio’s CEO was interviewed for an article in Fortune about developing an oral treatment for COVID-19. The reporter, Emily Mullin, writes: Even with highly effective vaccines, cases of…
“The conversation has all been about vaccines because really, people just want this to go away,” says Vikram Sheel Kumar, CEO of Clear Creek Bio. “The problem is that COVID-19…
CAMBRIDGE, Mass., November 20, 2020 – Clear Creek Bio, Inc. announced today that the company has dosed the first patient in the CRISIS2 study, a Phase 2 clinical study evaluating…
The multimodal mechanism of action of brequinar has the potential to treat COVID-19 by depleting the host nucleotide pool to block viral RNA synthesis CAMBRIDGE, Mass., September 1, 2020 –…
© Clear Creek Bio, 2021 | Privacy Policy | Terms | Design by Ape to Zebra
